|
Match
|
Document |
Document Title |
|
|
US20140213510 |
USE OF PLEITROPHIN FOR PREVENTING AND TREATING PANCREATIC DISEASES AND/OR OBESITY AND/OR METABOLIC SYNDROME
The present invention discloses the protein pleitrophin secreted by the developing pancreas, and polynucleotides, which identify and encode this protein. The invention also relates to the use of... |
|
|
US20120129766 |
METHODS OF TREATING FGF21-ASSOCIATED DISORDERS
The invention relates to the identification of new polypeptide and protein variants of fibroblast growth factor 21 (FGF21) that have improved pharmaceutical properties. Also disclosed are methods... |
|
|
US20110144006 |
PROTEIN COMPOSITION
The invention relates to a protein composition which upon ingestion by a healthy person with a normal fasting insulin level between 3.0-8.0 μU/L increases the insulin level to at most 20.0 μU/L.... |
|
|
US20140107025 |
OCULAR DRUG DELIVERY SYSTEM
An ocular drug delivery system including a composition in which a formulation having an active agent such as rHGH and or an rHGH mimic, e.g., that increases insulin growth factor (IGF) or that... |
|
|
US20140171361 |
METHODS FOR TREATING METABOLIC DISORDERS USING FGF
The method provides methods and compositions for treating metabolic disorders such as impaired glucose tolerance, elevated blood glucose, insulin resistance, dyslipidaemia, obesity, and fatty liver. |
|
|
US20110002994 |
METHOD OF REGULATING THE TH17 PATHWAY AND ITS ASSOCIATED METABOLIC IMPACT
It is disclosed a method of immunomodulating an immune response in a subject comprising administering to a subject a malleable protein matrix (MPM), from fermented whey, in an amount effective to... |
|
|
US20120329710 |
Methods of Inducing Regulated Pancreatic Hormone Production in Non-Pancreatic Islet Tissues
Disclosed are methods and pharmaceutical compositions for inducing pancreatic hormone production. |
|
|
US20120046224 |
TREATMENT OF DIABETES AND METABOLIC SYNDROME
Enterally administered calcitonin family members other than amylin, particularly calcitonin itself, are effective to treat Type I diabetes, Type II diabetes or metabolic syndrome, for mitigating... |
|
|
US20130130976 |
METHODS OF TREATING AUTOIMMUNE DISEASES OF THE CENTRAL NERVOUS SYSTEM (CNS) AND NEURODEGENERATIVE DISEASES
An insulin degrading enzyme (IDE) inhibitor for use in the treatment of a disease selected from the group consisting of an autoimmune disease of the central nervous system and a neurodegenerative... |
|
|
US20130136738 |
Methods of Treating Glucose Metabolism Disorders
Methods of treating individuals with a glucose metabolism disorder, and compositions thereof, are provided. |
|
|
US20130130975 |
Methods of Treating Glucose Metabolism Disorders
Methods of treating individuals with a glucose metabolism disorder, and compositions thereof, are provided. |
|
|
US20130017994 |
Methods of Treating Glucose Metabolism Disorders
Methods of treating individuals with a glucose metabolism disorder, and compositions thereof, are provided. |
|
|
US20150005233 |
TREATMENT OF HYPOGLYCEMIA
This invention provides compounds, compositions, and methods for treating hypogly. |
|
|
US20140227265 |
METHOD OF TREATING OR AMELIORATING METABOLIC DISORDERS USING CLEC-2
Methods of treating metabolic diseases and disorders using a Clec-2 extracellular domain are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, elevated glucose... |
|
|
US20140051630 |
PERIOSTIN-INDUCED PANCREATIC REGENERATION
A method for regenerating pancreatic tissue using recombinant periostin protein, a nucleic acid encoding said periostin and pharmaceutical compositions comprising said periostin are disclosed.... |
|
|
US20140315799 |
Compositions and Methods for Regulating Glucose Metabolism
The present disclosure provides compositions for regulating glucose metabolism. The compositions provide for reduced levels of p75NTR and/or reduced binding of p75NTR to a GTPase such as Rab31 or... |
|
|
US20130210713 |
COLLAGEN POWDER
The invention is directed to a method for preparing a collagen powder and to collagen powder that can be used for the preparation of a satiety inducing food product. The collagen powder of the... |
|
|
US20120028893 |
Adenovirus 36 E4 ORF 1 Gene and Protein and Their Uses
Expression of the E4 orf 1 gene of Ad-36 alone has been discovered to be responsible for the increased insulin sensitivity observed in Ad-36 infected animals, including increased adipogenesis.... |
|
|
US20140309163 |
FIBRONECTIN BASED SCAFFOLD DOMAIN PROTEINS THAT BIND TO MYOSTATIN
The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat... |
|
|
US20140107020 |
FIBRONECTIN BASED SCAFFOLD DOMAIN PROTEINS THAT BIND TO MYOSTATIN
The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat... |
|
|
US20140105896 |
FIBRONECTIN BASED SCAFFOLD DOMAIN PROTEINS THAT BIND TO MYOSTATIN
The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat... |
|
|
US20120046221 |
ALBUMIN FUSION PROTEINS
The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors... |
|
|
US20130190230 |
COMPOSITIONS AND METHODS FOR TREATING COGNITIVE DEFICITS
A method of treating or preventing cognitive impairment deficits in subjects with age-associated cognitive decline or a dementing illness includes administering to the subject a therapeutically... |
|
|
US20140336109 |
MODULATION OF GHRELIN LEVELS AND GHRELIN/UNACYLATED GHRELIN RATIO USING UNACYLATED GHRELIN
A method and a composition for decreasing ghrelin levels and/or decreasing ghrelin/unacylated ghrelin ratio in a subject, the method comprising administering an effective amount of unacylated... |
|
|
US20130157936 |
MODULATION OF GHRELIN LEVELS AND GHRELIN/UNACYLATED GHRELIN RATIO USING UNACYLATED GHRELIN
A method and a composition for decreasing ghrelin levels and/or decreasing ghrelin/unacylated ghrelin ratio in a subject, the method comprising administering an effective amount of unacylated... |
|
|
US20110166066 |
CATESTATIN (CST) AND ITS VARIANTS FOR TREATMENT OF CARDIOVASCULAR AND METABOLIC DISORDERS
Circulating levels of catestatin (Cts: human chromogranin A352-372) decrease in the plasma of patients with essential hypertension. Genetic ablation of the chromogranin A (Chga) gene in mice... |
|
|
US20140073563 |
FUSION PROTEINS FOR TREATING A METABOLIC SYNDROME
The invention is directed to a fusion protein comprising at least one FGF-21 (fibroblast growth factor-21) compound and at least one GLP-1R (glucagon-like peptide-1 receptor) agonist as well as to... |
|
|
US20120142582 |
Combination of Dopamine Agonists Plus First Phase Secretagogues for the Treatment of Metabolic Disorders
The present invention is directed to a method of treating a metabolic disorder or key elements of a metabolic disorder such method comprising the use of an agent(s) that increases central... |
|
|
US20150024995 |
Combination Of Dopamine Agonists Plus First Phase Insulin Secretagogues For The Treatment Of Metabolic Disorders
The present invention is directed to a method of treating a metabolic disorder or key elements of a metabolic disorder such method comprising the use of an agent(s) that increases central... |
|
|
US20150010508 |
Methods And Compositions Relating To Islet Cell Neogenesis
The present invention provides methods and kits for treating diseases and conditions associated with impaired pancreatic function. The present invention further provides methods of stimulating... |
|
|
US20150099697 |
METHOD FOR REVERSING RECENT-ONSET TYPE 1 DIABETES (T1D) BY ADMINISTERING SUBSTANCE P (sP)
Described herein is a treatment comprising the following step: (a) injecting a therapeutically effective amount of a pharmaceutical composition into the celiac artery of an individual, wherein the... |
|
|
US20120058938 |
NUTRITIONAL COMPOSITION INDUCING A POSTPRANDIAL ENDOCRINE RESPONSE
The invention concerns the use of a nutritional composition for the treatment of disorders which are associated with malfunctioning in the uptake and use of food-derived energy in the human body.... |
|
|
US20140357556 |
Novel Target for Diagnosis and Treatment of Diabetes and Cardiovascular Diseases
Diagnostic, prognostic, and treatment methods, compositions, and kits for enhancing insulin secretion and beta cell numbers and functions, and controlling glycemia associated with diabetes,... |
|
|
US20140243259 |
GLYCOPROTEINS HAVING LIPID MOBILIZING PROPERTIES AND THERAPEUTIC USES THEREOF
The invention provides compositions and methods for ameliorating symptoms associated with hyperglycemia by administering a Zn-α2-glycoprotein or a functional fragment thereof, methods of... |
|
|
US20070299010 |
CPG15 and CPG15-2 compounds and inhibitors as insulin receptor and insulin-like growth factor receptor agonists and antagonists
Disclosed herein are CPG15 and CPG15-2 compounds and inhibitors that act as agonists and antagonists of the insulin receptor and insulin-like growth factor receptors, and the use of such... |
|
|
US20070072810 |
Agent for treating diabetes
An agent for treating diabetes with sulfonylurea secondary failure which comprises a dipeptidyl peptidase IV inhibitor. The agent of the present invention is an agent for treating diabetes with... |
|
|
US20150126438 |
Novel ChREBP Isoforms and Methods Using the Same
The invention provides diagnostic and prognostic methods and methods of evaluating treatment protocols for disorders such as obesity, diabetes, metabolic syndrome, cancer and vascular disease by... |
|
|
US20130123172 |
Treatment of Type 2 Diabetes With FTY720
The present disclosure provides therapeutic methods for prevention and treatment of type-2 diabetes comprising administering to the subject an effective amount of FTY720 or an analog. |
|
|
US20050113287 |
Composition to enhance joint function and repair
The present invention relates to a composition to enhance joint function, reduce inflammation and homocysteine levels, and repair cartilage. The present invention relates to a nutritional... |
|
|
US20150182597 |
COMPOSITIONS COMPRISING HYALURONIC ACID AND DERMATAN SULPHATE FOR THE TREATMENT OF BEING OVERWEIGHT AND OBESITY
The present invention relates to a composition comprising hyaluronic acid and dermatan sulphate for use in the treatment or prevention of overweight, obesity, insulin resistance, type 2 diabetes,... |
|
|
US20140107026 |
BONE MORPHOGENETIC PROTEINS FOR THE TREATMENT OF INSULIN RESISTANCE
The present disclosure relates to compositions and methods for treating insulin resistance and/or obesity in a cell and/or a subject |
|
|
US20130109621 |
METHODS FOR INCREASING INSULIN SECRETION BY CO-STIMULATION OF CORTICOTROPIN-RELEASING FACTOR RECEPTORS
Methods and compositions are provided for stimulating insulin production, increasing beta cell mass, or decreasing beta cell loss in a subject. For example, methods of the embodiments can comprise... |
|
|
US20130085100 |
New Uses of Oxytocin-Like Molecules and Related Methods
The present invention is directed to a derivative selected from oxytocin, an oxytocin derivative, and an oxytocin agonist useful for the treatment of a disorder selected from obesity and insulin... |
|
|
US20060287251 |
Combination therapy for glycaemic control
The present invention relates to method of treatment, in particular to a method for the treatment of diabetes mellitus, especially non-insulin dependent diabetes mellitus (NIDDM) or Type 2... |
|
|
US20110319317 |
TREATMENT OF SIRTUIN 1 (SIRT1) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO SIRT1
The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Sirtuin 1 (SIRT1), in particular, by targeting natural antisense polynucleotides of... |
|
|
US20130195807 |
AGONISTS OF GROWTH HORMONE RELEASING HORMONE AS EFFECTORS FOR SURVIVAL AND PROLIFERATION OF PANCREATIC ISLETS
Agonists of growth hormone releasing hormone promote islet graft growth and proliferation in patients. Methods of treating patients comprise the use of these agonists. |
|
|
US20100318060 |
Injection Device With Rotatable Dose Setting
An injection device comprising a housing and a dose setting mechanism including a dose setting element. Contrary to prior art injection devices, the dose setting element can only be set at a few... |
|
|
US20150231204 |
PANCREATIC POLYPEPTIDE FAMILY MOTIFS, POLYPEPTIDES AND METHODS COMPRISING THE SAME
The present invention provides novel Pancreatic Polypeptide Family (“PPF”) polypeptides and methods for their use. |
|
|
US20150258208 |
PEGYLATED OXM VARIANTS
A composition which includes oxyntomodulin and polyethylene glycol polymer (PEG polymer) linked via a reversible linker such as 9-fluorenylmethoxycarbonyl (Fmoc) or... |
|
|
US20150148289 |
PEGYLATED OXM VARIANTS
A composition which includes oxyntomodulin and polyethylene glycol polymer (PEG polymer) linked via a reversible linker such as 9-fluorenylmethoxycarbonyl (Fmoc) or... |